Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine for resistant obsessive-compulsive disorder
IRCT20190726044339N3Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in obsessive compulsive disorder (OCD) comparing Agomelatine + sertraline with Placebo + sertraline (2 arms). Primary endpoint: Severity of obsession based on Y-BOCS questionnaire. Started Nov 2020; status: completed.
02
Drugs
agomelatine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20190726044339N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190726044339N3.